what the research shows
BPC-157 Benefits in the Research Literature: Tendon, Gut, and Vascular Repair
The breadth of the preclinical record on one page — tendon and bone repair, gut cytoprotection, angiogenesis, and distant-organ protection — every benefit chalked to its study.
BPC-157 benefits, drawn from the preclinical record
BPC-157 benefits, as measured in research, span an unusually wide range of tissues for a single peptide. In preclinical work, BPC-157 has been studied for tendon, ligament, bone, and muscle repair, gastric-ulcer and gut cytoprotection, angiogenesis, nerve regeneration, and distant-organ protection [5]. The unifying thread is cytoprotection delivered through new blood-vessel formation [3].
Every item on that list is an animal-model or early-pilot finding, not an approved human use [11]. The breadth is real and reproducible across models, which is itself a finding worth surfacing — but breadth in rodents is not the same as proven benefit in people. This page reads the strongest benefit findings tissue by tissue, and keeps the human caveat in view throughout.
What are the potential uses and benefits of BPC-157?
In preclinical research BPC-157 has been studied for tendon, ligament, bone, and muscle repair, gastric-ulcer and gut cytoprotection, angiogenesis, nerve regeneration, and distant-organ protection [5]. These are animal-model and early-pilot findings, not approved human uses [11]. The most consistent mechanism behind them is angiogenesis via the VEGFR2-Akt-eNOS pathway [3].
BPC-157 and Tendon, Ligament, and Bone Repair
Tendon repair is BPC-157's flagship musculoskeletal finding. In a 2003 study, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in vitro [1]. Wistar rats received 10 µg, 10 ng, or 10 pg per rat by intraperitoneal injection once daily, with local delivery also tested; treated tendons showed improved biomechanical and functional recovery, better collagen organization, and restored tendon integrity versus untreated controls [1].
The tendon-and-musculoskeletal repair research extends from that result into ligament and bone models, consolidated in the 2021 wound-healing review around the same cytoprotective and angiogenic mechanism [5]. The 2003 transected-Achilles study remains the most cited single demonstration that the peptide can speed structural tissue repair in an animal model.
Gut and gastric cytoprotection
The gut is where BPC-157 was first characterized. A 2004 rat study reported reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric and an ulcer-formation inhibition ratio of 45.7-65.6% at the higher doses (400 ng/kg and 800 ng/kg) [4]. Healing came with faster rebuilding of the glandular epithelium and granulation tissue [4]. This cytoprotective gut activity is the historical anchor of the entire BPC-157 research program and the reason it carries the Body Protection Compound name [5].
Angiogenesis and vascular repair
Vascular repair is the mechanism that makes the rest cohere. In a 2017 study, BPC-157 up-regulated VEGFR2 and promoted its internalization, activating the VEGFR2-Akt-eNOS pathway and increasing vessel density in vitro and in vivo [3]. In ischemic muscle, blood-flow recovery accelerated [3]. Because nearly every tissue BPC-157 helps depends on perfusion to heal, the VEGFR2 angiogenesis mechanism is the most plausible single explanation for its breadth — better blood supply, faster repair.
Distant-organ and recent findings
BPC-157's protective effects in animal models reach beyond the site of injury. A 2025 rat study reported that BPC-157 reduced distant-organ damage in the liver, kidney, and lung secondary to acute pancreatitis [12]. A 2026 rat study reported resolution of a tracheocutaneous fistula, attributed to nitric-oxide-system involvement [13]. A 2025 review emphasized the peptide's reported safety profile and beneficial effects following various intoxications in preclinical models [14]. These are recent, mechanistically interesting, and entirely preclinical — additions to the rodent record, not evidence of human benefit [11].